Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$7.63 USD
-0.09 (-1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $7.64 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.63 USD
-0.09 (-1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $7.64 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Zacks News
Universal Health (UHS) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Universal Health's (UHS) fourth-quarter results are likely to reflect an increase in same facility adjusted admissions in acute care hospitals.
Halozyme Therapeutics (HALO) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 2.13% and 2.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Select Medical's (SEM) fourth-quarter results are likely to reflect improved figures in the Rehabilitation Hospital business.
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Q4 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Ultragenyx (RARE) reports a wider loss in the fourth quarter while revenues increase on growth in demand for its drugs.
Can Teladoc's (TDOC) Q4 Earnings Beat on Growing Visits?
by Zacks Equity Research
The fourth-quarter results of Teladoc Health (TDOC) are likely to reflect a rise in visits and memberships.
Vir Biotechnology, Inc. (VIR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q4 results are likely to be impacted by foreign exchange rate fluctuations. With the Biocon deal closed, investors await its impact on the 2023 guidance.
Pediatrix Medical (MD) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Pediatrix Medical's (MD) fourth-quarter results are likely to reflect higher operating expenses and patient volume growth.
GSK's Beats on Q4 Earnings & Sales, Issues Upbeat 2023 Outlook
by Zacks Equity Research
GSK's (GSK) revenues benefit from strong growth in sales across all segments, especially Shingrix vaccine sales. The company also issues fresh 2023 guidance for all its segments.
GSK Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix and Juluca to drive fourth-quarter sales.
Dr. Reddy's (RDY) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) beat earnings and revenues in the fiscal third quarter, driven by growth in the United States and Russian markets.
FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld
by Zacks Equity Research
AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.
Vir Biotechnology, Inc. (VIR) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Editas (EDIT) Moves Ahead With its Portfolio Reprioritization
by Zacks Equity Research
Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise.
Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
by Zacks Equity Research
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
Should Value Investors Buy Vir Biotechnology (VIR) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Ligand Pharmaceuticals (LGND) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
by Zacks Equity Research
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
Is Biogen (BIIB) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 71%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 70.9% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Should Value Investors Buy Vir Biotechnology (VIR) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
5 Winning Stocks Backed by the Overlooked Rising P/E Trick
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap AMC Entertainment (AMC), Live Nation Entertainment (LYV), CuriosityStream (CURI), Helius Medical Technologies (HSDT) and Vir Biotechnology (VIR).
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.